Literature DB >> 2447792

Calmodulin antagonists depress calcium and potassium currents in ventricular and vascular myocytes.

U Klöckner1, G Isenberg.   

Abstract

Myocytes isolated from guinea pig ventricles or bovine portal veins were voltage clamped with a single patch electrode. The calmodulin antagonists (CaM-A) calmidazolium, trifluoperazine (TFP), and chlorpromazine acted as Ca antagonists; they reduced the calcium inward current ICa in a voltage- and use-dependent way. For ventricular myocytes, 50% effective concentration (EC50) of calmidazolium was 1 microM, and the EC50 for TFP was 2.5 microM. For vascular myocytes, these numbers were 0.3 and 1 microM, respectively. CaM-A moderately retarded the inactivation time course and shifted the ICa availability curve to more negative potentials. CaM-A were not selective Ca antagonists; other membrane currents such as sodium currents and inwardly and delayed potassium currents were reduced as well (EC50 between 5 and 10 microM). It is unlikely that the above effects require binding of CaM-A to Ca-calmodulin, since reduction of ICa or potassium current (IK) was not modified when 1) the cells were loaded with 100 microM exogenous calmodulin or 2) Ca ions were removed from the extra- and intracellular space. Instead, the unspecific reduction of membrane currents may result from a change in the lipids of the sarcolemma into which CaM-A partition and accumulate.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2447792     DOI: 10.1152/ajpheart.1987.253.6.H1601

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  22 in total

1.  Effects of calmodulin antagonists on calcium-activated potassium channels in pregnant rat myometrium.

Authors:  M Kihira; K Matsuzawa; H Tokuno; T Tomita
Journal:  Br J Pharmacol       Date:  1990-06       Impact factor: 8.739

2.  Inhibition of a mammalian large conductance, calcium-sensitive K+ channel by calmodulin-binding peptides.

Authors:  A P Braun; E K Heist; H Schulman
Journal:  J Physiol       Date:  2000-09-15       Impact factor: 5.182

3.  Chlorpromazine inhibits store-operated calcium entry and subsequent noradrenaline secretion in PC12 cells.

Authors:  S Y Choi; Y H Kim; Y K Lee; K T Kim
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 4.  P2X receptors as drug targets.

Authors:  R Alan North; Michael F Jarvis
Journal:  Mol Pharmacol       Date:  2012-12-19       Impact factor: 4.436

5.  Trifluoperazine enhancement of Ca2+-dependent inactivation of L-type Ca2+ currents in Helix aspersa neurons.

Authors:  H Cruzblanca; S M Gamiño; J Bernal; F J Alvarez-Leefmans
Journal:  Invert Neurosci       Date:  1998-03

6.  Role of calmodulin in the activation of carbachol-activated cationic current in guinea-pig gastric antral myocytes.

Authors:  S J Kim; S C Ahn; I So; K W Kim
Journal:  Pflugers Arch       Date:  1995-09       Impact factor: 3.657

7.  The effect of a chemical phosphatase on single calcium channels and the inactivation of whole-cell calcium current from isolated guinea-pig ventricular myocytes.

Authors:  T J Allen; R A Chapman
Journal:  Pflugers Arch       Date:  1995-05       Impact factor: 3.657

8.  Blockade by calmodulin inhibitors of Ca2+ channels in smooth muscle from rat vas deferens.

Authors:  K Nakazawa; K Higo; K Abe; Y Tanaka; H Saito; N Matsuki
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

9.  Fendiline inhibits L-type calcium channels in guinea-pig ventricular myocytes: a whole-cell patch-clamp study.

Authors:  O Tripathi; W Schreibmayer; H A Tritthart
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

Review 10.  Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org).

Authors:  Pieter G Postema; Christian Wolpert; Ahmad S Amin; Vincent Probst; Martin Borggrefe; Dan M Roden; Silvia G Priori; Hanno L Tan; Masayasu Hiraoka; Josep Brugada; Arthur A M Wilde
Journal:  Heart Rhythm       Date:  2009-07-08       Impact factor: 6.343

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.